trials

Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021. These updates will be discussed during a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:50 a.m. PST / 10:50 a.m. EST.

“I’m exceptionally proud of the entire Magenta team who continued to adapt and execute across our portfolio, despite the disruptions that characterized 2020. This past year, we continued to drive our vision to bring immune and blood systems reset to more patients. We announced four pipeline-expanding partnerships, presented clinical and pre-clinical data across our pipeline and secured the capital that we expect can fund our operations into 2023. We continue to advance four

Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials – Press Release

CAMBRIDGE, Mass.–(Business Wire)–Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021. These updates will be discussed during a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:50 a.m. PST / 10:50 a.m. EST.

“I’m exceptionally proud of the entire Magenta team who continued to adapt and execute across our portfolio, despite the disruptions that characterized 2020. This past year, we continued to drive our vision to bring immune and blood systems reset to more patients. We announced four pipeline-expanding partnerships, presented clinical and pre-clinical data across our pipeline and secured the capital that we expect can fund our operations into 2023. We continue

COVID-19 vaccine trials make development, but what does that indicate for you?

— FOR COVID-19. DID YOU Register On the internet? WILL YOU FILL OUT THIS PAPER FOR ME? FOR HUNDREDS OF MARYLANDERS IN HOWARD COUNTY, MONDAY WAS MARKED BY Waiting. I’M Below Since MY Continue to be Had Publicity, SO I Had TO GET Tested JUST TO MAKE Sure. Ready IN LINE, IN THE POURING RAIN, TO GET Tested FOR COVID-19. They are Commencing TO GET Lengthier. WHEN WE WENT On the internet WE Were being SUPRISED THAT YOU Couldn’t GET AN APPOINTMENT Wherever IN THE Condition. WE Tried out Quite a few Unique Web sites AND THEY ALL Mentioned It is As well Chaotic. THIS Comes, AMID NEW DEVELOPMENTS ON THE VACCINE Entrance. DRUG-MAKER MODERNA, LIKE PFIZER Just before IT, Asking THE Food and drug administration TO Quick-Keep track of It’s CORONAVIRUS VACCINE. MODERNA Claims Medical TRIALS SO Significantly, Present It is Extremely Successful IN Preventing THE VIRUS. AND WE …